Pitt
UPMC
UPCI
CMU
Ahmad Tarhini, M.D.
Assistant Professor
Department of Medicine
University of Pittsburgh
HCC, Room 555
5150 Centre Avenue
Pittsburgh, PA 15232
office: 412-648-6507
fax: 412-648-6579
email: tarhiniaa@upmc.edu
I am involved in the development, implementation, and analysis of clinical and translational melanoma research projects. Specifically, these projects focus on: biotherapeutic treatment regimens for patients with metastatic melanoma; a clinical trial of a targeted anti-angiogenic therapeutic agent for advanced melanoma; and translational projects evaluating prognostic and predictive biomarkers for patients with melanoma.
Tarhini AA, Kirkwood JM (2008). Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther. 8: 1583-1593.
Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS (2008). A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer 113: 1632-1640.
Tarhini AA, Kirkwood JM, Tawbi H, Gooding WE, Islam MF, Agarwala SS (2008). Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer 112: 1131-1138.
Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS (2007). Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 25: 3802-3807.